在胰岛素治疗的2型糖尿病成人中,间歇扫描式持续葡萄糖监测相较血糖监测与更低的HbA1c及糖尿病相关并发症住院风险降低相关
这项瑞典回顾性比较队列研究纳入2017年6月1日后启动间歇扫描式持续葡萄糖监测(isCGM)的胰岛素治疗2型糖尿病成人,分为每日多次胰岛素注射组(T2D-MDI,2876例)和基础胰岛素组(T2D-B,2292例),分别匹配33584例和43424例毛细血管血糖监测(BGM)对照。isCGM使用者6个月时HbA1c变化较对照的基线校正差值在T2D-MDI组为-3.7 mmol/mol(-0.34%)、T2D-B组为-3.5 mmol/mol(-0.32%),并维持至24个月;T2D-MDI组isCGM使用者严重低血糖、卒中、急性非致死性心肌梗死及任何原因住院的RR显著降低,T2D-B组心力衰竭住院及任何原因住院的RR降低。
要点
- T2D-MDI组isCGM使用者6个月HbA1c变化较BGM对照的基线校正差值为-3.7 mmol/mol(-0.34%),维持至24个月。
- T2D-B组isCGM使用者6个月HbA1c变化较BGM对照的基线校正差值为-3.5 mmol/mol(-0.32%),维持至24个月。
- T2D-MDI组isCGM使用者严重低血糖、卒中、急性非致死性心肌梗死及任何原因住院的RR显著低于BGM对照。
主要发现
- T2D-MDI队列中isCGM使用者较BGM对照的HbA1c变化基线校正差值在6个月为-3.7 mmol/mol(-0.34%),并维持至24个月。
- T2D-B队列中isCGM使用者较BGM对照的HbA1c变化基线校正差值在6个月为-3.5 mmol/mol(-0.32%),并维持至24个月。
- T2D-MDI队列中isCGM使用者较BGM对照,严重低血糖入院RR为0.51(95%CI 0.27,0.95)。
- T2D-MDI队列中isCGM使用者较BGM对照,卒中入院RR为0.54(95%CI 0.39,0.73),急性非致死性心肌梗死入院RR为0.75(95%CI 0.57,0.99),任何原因住院RR为0.84(95%CI 0.77,0.90)。
- T2D-B队列中isCGM使用者较BGM对照,心力衰竭入院RR为0.63(95%CI 0.46,0.87),任何原因住院RR为0.76(95%CI 0.69,0.84)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: We assessed the impact of initiating intermittently scanned continuous glucose monitoring (isCGM) compared with capillary blood glucose monitoring (BGM) on HbA1c levels and hospitalisations for diabetes-related complications in adults with insulin-treated type 2 diabetes in Sweden. METHODS: This retrospective comparative cohort study included adults with type 2 diabetes who had a National Diabetes Register initiation date for isCGM after 1 June 2017. Prescribed Drug Register records identified subgroups treated with multiple daily insulin injections (T2D-MDI) or basal insulin (T2D-B), with or without other glucose-lowering drugs. The National Patient Register provided data on hospitalisation rates. RESULTS: We identified 2876 adults in the T2D-MDI group and 2292 in the T2D-B group with an isCGM index date after 1 June 2017, matched with 33,584 and 43,424 BGM control participants, respectively. The baseline-adjusted difference in the change in mean HbA1c for isCGM users vs BGM control participants in the T2D-MDI cohort was -3.7 mmol/mol (-0.34%) at 6 months, and this was maintained at 24 months. The baseline-adjusted difference in the change in HbA1c for isCGM users vs BGM control participants in the T2D-B cohort was -3.5 mmol/mol (-0.32%) at 6 months, and this was also maintained at 24 months. Compared with BGM control participants, isCGM users in the T2D-MDI cohort had a significantly lower RR of admission for severe hypoglycaemia (0.51; 95% CI 0.27, 0.95), stroke (0.54; 95% CI 0.39, 0.73), acute non-fatal myocardial infarction (0.75; 95% CI 0.57, 0.99) or hospitalisation for any reason (0.84; 95% CI 0.77, 0.90). isCGM users in the T2D-B cohort had a lower RR of admission for heart failure (0.63; 95% CI 0.46, 0.87) or hospitalisation for any reason (0.76; 95% CI 0.69, 0.84). CONCLUSIONS/INTERPRETATION: This study shows that Swedish adults with type 2 diabetes on insulin who are using isCGM have a significantly reduced HbA1c and fewer hospital admissions for diabetes-related complications compared with BGM control participants.
引用
- Nathanson D, Eeg-Olofsson K, Spelman T, et al. Intermittently scanned continuous glucose monitoring compared with blood glucose monitoring is associated with lower HbA1c and a reduced risk of hospitalisation for diabetes-related complications in adults with type 2 diabetes on insulin therapies. Diabetologia. 2024. PMID: 39460755. doi:10.1007/s00125-024-06289-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。